An amended initial statement of beneficial ownership was filed on November 4, 2026, disclosing director Robert A. Scott's holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) as of the event date of October 23, 2026.

Key Highlights

  • Reporting person: Robert A. Scott, identified as a director of Arcutis Biotherapeutics, Inc.
  • Beneficial ownership: 17,523 shares of common stock held indirectly through The Scott Family Trust
  • Trust structure: The Scott Family Trust is dated January 31, 2020, with Scott serving as a trustee
  • Event date: October 23, 2026, with the original filing dated October 28, 2026
  • Disclaimer: Scott disclaims beneficial ownership except to the extent of his pecuniary interest in the trust
  • No derivative securities: No derivative securities were reported in Table II of the filing

Director Scott's Initial Ownership Disclosure for Arcutis Biotherapeutics

According to the filing, Robert A. Scott submitted an amended initial statement of beneficial ownership in connection with his role as a director of Arcutis Biotherapeutics, Inc., a biopharmaceutical company listed on NASDAQ:ARQT. The event requiring the statement occurred on October 23, 2026, and the amendment was filed on November 4, 2026, with the original statement having been filed on October 28, 2026.

The filing disclosed that Scott indirectly holds 17,523 shares of Arcutis common stock through The Scott Family Trust dated January 31, 2020, of which he is a trustee. The filing states that Scott "disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein," and notes that inclusion of these shares in the report "shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes." No derivative securities, such as options or warrants, were reported in Table II of the disclosure. The filing was signed by Latha Vairavan as attorney-in-fact for Robert A. Scott on November 4, 2026.

What Was Disclosed

This amended initial beneficial ownership statement discloses that Arcutis Biotherapeutics director Robert A. Scott indirectly holds 17,523 shares of common stock through The Scott Family Trust, with no derivative securities reported. The filing covers the event date of October 23, 2026.